Recently, in high-grade serous ovarian carcinoma (HGSOC), the most frequent ovarian cancer histotype carrying p53 mutation in 96% of cases, animal and clinical data have indicated the ability of MDM4 to confer cell sensitivity to platinum, the elective treatment for EOC, and the association of its subcellular localization with clinical prognosis9. Here, MDM4 is linked to ovarian carcinoma.